Position in AMGN
as of Jun 30, 2026
· filed Jul 23, 2026
Position Value
$698,529
+$17,701 QoQ
Shares Held
1,929
-0.3% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.24%
of 13F equity value
Holder Rank
#1,959
of 3,140 holders
Holding Since
Dec 2023
11 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in AMGN Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Onyx Bridge Wealth Group LLC holds $11,019,132 across 8 Drug Manufacturers - General names. AMGN ranks #6 (6.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | MRK |
Merck & Co., Inc.
|
20,486 | $2,632,451 | |
| 2 | LLY |
ELI LILLY & Co
|
1,920 | $2,302,905 | |
| 3 | ABBV |
AbbVie Inc.
|
6,409 | $1,612,760 | |
| 4 | JNJ |
Johnson & Johnson
|
5,983 | $1,519,501 | |
| 5 | PFE |
Pfizer Inc
|
48,247 | $1,161,786 | |
| 6 | AMGN |
Amgen Inc
This page
|
1,929 | $698,529 | |
| 7 | GILD |
Gilead Sciences, Inc.
|
4,931 | $622,981 | |
| 8 | BMY |
Bristol Myers Squibb Co
|
8,126 | $468,219 |
All Filings in AMGN
Export CSV
11 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $698,529 | 1,929 | Shares | Sole | 2026-07-23 | |
| 2026-03-31 | $680,828 | 1,935 | Shares | Sole | 2026-04-22 | |
| 2025-12-31 | $613,705 | 1,875 | Shares | Sole | 2026-02-18 | |
| 2025-09-30 | $502,316 | 1,780 | Shares | Sole | 2025-11-06 | |
| 2025-06-30 | $429,424 | 1,538 | Shares | Sole | 2025-07-30 | |
| 2025-03-31 | $445,516 | 1,430 | Shares | Sole | 2025-04-29 | |
| 2024-12-31 | $370,630 | 1,422 | Shares | Sole | 2025-01-27 | |
| 2024-09-30 | $439,816 | 1,365 | Shares | Sole | 2024-10-17 | |
| 2024-06-30 | $423,369 | 1,355 | Shares | Sole | 2024-07-22 | |
| 2024-03-31 | $392,361 | 1,380 | Shares | Sole | 2024-04-29 | |
| 2023-12-31 | $392,571 | 1,363 | Shares | Sole | 2024-01-31 | |
| No filing history on record for this holder in this stock. | ||||||